Back to Results

A Phase 3, Randomized, Adaptive Dose-Selection, Multi-Regional, Double- Masked, Parallel-Group, 3-Month Trial Evaluating the Safety and Efficacy of NCX 470 vs. Latanoprost 0.005% in Subjects with Open-Angle Glaucoma or Ocular Hypertension (Mont Blanc)

Study

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Malik Kahook,  MD

Malik Kahook, MD

Study ID

Protocol Number: 20-0637

More information available at ClinicalTrials.gov: NCT04445519

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers